Sanofi announced an evolution of its Executive Committee effective September 1, 2026, bringing together a focused leadership team as the company prepares its next strategic chapter. The new committee includes François Roger as Executive Vice President of Finance, Paulo Fontoura as Executive Vice President and Head of Research & Development, Manuela Buxo as Executive Vice President of Specialty Care, Thomas Triomphe as Executive Vice President of Vaccines, Thomas Grenier as Executive Vice President of General Medicines, Brendan O'Callaghan as Executive Vice President of Manufacturing & Supply, Jamie Haney as Executive Vice President and General Counsel, and Véronique Jaillet as Executive Vice President and Chief People Officer ad interim. Emmanuel Frenehard, Head of Digital, and Audrey Duval, Head of Corporate Affairs, will continue to report directly to CEO Belén Garijo. Madeleine Roach, currently Head of Business Operations, will become President and Country Lead of Sanofi Germany, Switzerland and Austria, while her current responsibilities will be integrated into the Finance function, which will also gain Global Partnering and Business Development. Thomas Triomphe will additionally assume responsibility for China. Olivier Charmeil, currently Executive Vice President of General Medicines, will transition to Strategic Projects Advisor to the CEO, and Roy Papatheodorou, currently Executive Vice President and General Counsel, has decided to leave the organization.
Sanofi SAExecutive Committee reshuffle announced; no clear positive or negative impact on strategy or operations
Banco Santander S.A.